San Diego-based mostly Viking Therapeutics marked alone as a serious competitor during the weight loss drug sector in February soon after revealing promising details from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection and in March the com